Aatru Medical Announces Latin America Distribution Agreement for Their

Innovative NPSIMS™ Negative Pressure Surgical Incision Management System

Aatru Medical, LLC (“Aatru”) is pleased to announce a Latin America distribution agreement with
Salus Biomedical, for the NPSIMS product. The patented NPSIMS utilizes a safe and innovative
solid-state chemical reaction to create and apply negative pressure in the therapeutic range to
closed incision sites for up to 7 days.

Cleveland, OH April 06, 2022 --(PR.com)-- As part of Aatru Medical, LLC (“Aatru”) commercial
planning, the company is pleased to announce a Latin America distribution agreement with Salus
Biomedical, for the NPSIMS product. The product received recent FDA 510(k) clearance, and Aatru is in
the process of finalizing market introduction plans. Initial markets include Latin America, with U.S. and
additional global markets to follow.

“We are very excited about this next phase of Aatru development, as we bring the product to market,
providing access for clinicians and patients to this truly innovative product,” stated Edward Armstrong,
President, Aatru Medical.

The patented NPSIMS utilizes a safe and innovative solid-state chemical reaction to create and apply
negative pressure in the therapeutic range to closed incision sites for up to 7 days. The unique
mode-of-action, which contains no moving parts or electromechanical components, delivers similar
clinical performance to other available Negative Pressure Wound Therapy (NPWT) devices, while
providing substantial advantages in patient quality of life, ease of use, and price.

Salus Biomedical is a medical device distributor across Latin America, focusing on hospital use devices.
Israel Vierma, Managing Director of Salus Biomedical, stated, “We are proud to be at the forefront of
incision care with this simple, most innovative and useful product. Aatru Medical is breaking new ground
on ease-of-use for the clinicians and in helping us address a growing need in Latin America.”

Aatru COO Tom Lash noted, “Market analysis and voice-of-customer feedback identified that users value
the role of NPWT products in helping manage the risk of surgical site infections (SSI), although product
complexity and the high cost of currently-available NPWT products is restricting use to mainly
higher-risk incisions only. The NPSIMS product provides similar clinical performance while providing
significant cost improvement over existing devices, creating a more scalable standard of care to treat the
vast majority of low-exudate surgical incisions.”

About NPWT for closed surgical incisions:

Several post-operative wound complications are common following surgical procedures. Negative
pressure wound therapy (NPWT) is well recognized for the management of open wounds, and in the last
several years has been applied to closed surgical incisions. Compared with standard postoperative
dressings, NPWT has been clinically shown to significantly reduce the rate of surgical site infection and
seroma.

Page 1 of 4
PR.com Press Release Distribution Terms
About Aatru Medical:
Aatru is a privately held medical device technology company focused on disrupting the surgical incision
market with its FDA-cleared NPSIMS, a simple, disposable, single-use, patented, low-cost NPWT device,
uniquely designed to require no electromechanical pump, battery or canister.

Introductory videos of the NPSIMS product can be found on the Aatru Medical, LLC website:
www.aatru.com.

Page 2 of 4
PR.com Press Release Distribution Terms
Contact Information:
Aatru Medical, LLC
Tom Lash
216-303-6063
Contact via Email
www.aatru.com

Online Version of Press Release:

https://www.pr.com/press-release/858683

Page 3 of 4
PR.com Press Release Distribution Terms
 Page 4 of 4
PR.com Press Release Distribution Terms